Profile of liver cholestatic biomarkers following prolonged ketamine administration in patients with COVID-19

BMC Anesthesiol. 2023 Feb 7;23(1):44. doi: 10.1186/s12871-023-02006-2.

Abstract

Background: To investigate the possible influence of prolonged ketamine (K) or esketamine (ESK) infusion on the profile of liver cholestatic biomarkers in patients with COVID-19 infection.

Methods: A retrospective analysis was performed on 135 patients with COVID-19 related ARDS who received prolonged K or ESK infusion. They were compared to 15 COVID-19 ICU patients who did not receive K/ESK while being mechanically ventilated and 108 COVID-19 patients who did not receive mechanical ventilation nor K/ESK. The profile of the liver function tests was analysed in the groups.

Results: Peak values of ALP, GGT and bilirubin were higher in the K/ESK group, but not for AST and ALT. Peak values of ALP were significantly higher among patients who underwent mechanical ventilation and who received K/ESK, compared with mechanically ventilated patients who did not receive K/ESK. There was a correlation between these peak values and the cumulative dose and duration of K/ESK therapy.

Conclusions: Based on the observations of biliary anomalies in chronic ketamine abusers, prolonged exposure to ketamine sedation during mechanical ventilation may also be involved, in addition to viral infection causing secondary sclerosing cholangitis. The safety of prolonged ketamine sedation on the biliary tract requires further investigations.

Keywords: ARDS; COVID-19; Cholangitis; Cholestasis; Ketamine/esketamine; Mechanical ventilation; Prolonged infusion.

MeSH terms

  • COVID-19*
  • Humans
  • Ketamine*
  • Liver
  • Retrospective Studies

Substances

  • Esketamine
  • Ketamine